KUALA LUMPUR, Oct 16 — Duopharma Biotech Berhad has signed a five-year exclusive agreement with Taiwan-based Enimmune Corporation for the distribution and sale of vaccines in Malaysia.
The partnership supports Duopharma Biotech’s biologics strategy to diversify its portfolio into specialty and higher-value health care segments, strengthen its capabilities through strategic partnerships, and meet evolving health care needs.
It also establishes a pathway to introduce niche vaccines in Malaysia and provides a foundation for collaboration on future vaccine pipeline opportunities.
“This partnership is a further step in strengthening our vaccine portfolio and building a sustainable presence in preventive health care. Our focus is on bringing niche vaccines to Malaysia that address unmet needs and complement the health care options available today,” said Duopharma Biotech Group Chief Executive Officer Wan Amir-Jeffery Wan Abdul Majid.
